Over the last decade, follow-up of the original Diabetes Control and Complications Trial (DCCT) cohort has revealed that individuals in end of the initial DCCT phase have usual glycemic control and continue to have better outcomes for microvascular and macrovascular events, although they have been randomized initially to a more intensified insulin regimen [16, 17]. This evidence concerns the gene INS and diabetes mellitus.